The pharmacokinetics of the analgesic flupirtine (ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3-yl] carbamate, D 9998) were examined in healthy volunteers after a single intravenous, peroral and rectal dose. Plasma-and urine concentrations were analysed by a photometric procedure specific for flupirtine and its active metabolite D 13223. The bioavailability from the capsule amounted to 90%, from the suppository to 72.5%. Plasma half-life was 8.5-10.7 h. No significant accumulation of the plasma concentrations after multiple peroral administration was observed. After a peroral dose of 14C-flupirtine the radioactivity is predominantly excreted via the urine (72%). Two metabolites could be isolated from urine and their chemical structure determined. Together with the parent drug they explain 54% of the urinary radioactivity. The metabolite D 13223 that still has some analgesic activity is found in plasma, too. The portion of unchanged flupirtine amounts to 56-83% of the total plasma levels.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Discovery of a novel K7.2/7.3 channels agonist for the treatment of neuropathic pain.
Eur J Med Chem
December 2024
Jiangsu Key Laboratory of Marine Biological Resources and Environment, Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China. Electronic address:
Article Synopsis
- The researchers developed and tested a series of new compounds that act as agonists for KCNQ2/3 channels, which are important for pain management.
- Among the compounds, compound 16 exhibited strong activity specifically for KCNQ2/3 channels with good effectiveness in pain models without causing liver damage.
- Additionally, compound 16 demonstrated low risk of toxicity, maintained good motor function, and had favorable pharmacokinetic properties, indicating its potential as a treatment for neuropathic pain.
Background: This research synthesized scientific evidence on the use of pharmacotherapy as intervention to reduce cognitive impairments in adult patients with primary central nervous system (CNS) infections.
Methods: We searched for experimental studies published in English prior to October 2021 in MEDLINE, Embase and Cochrane databases. We included non-randomized studies (NRS) and randomized control trials (RCT) of pharmacotherapy versus placebo, drug, or a combination of drugs in adults with primary CNS infection.
Pain management after elective craniotomy: A systematic review with procedure-specific postoperative pain management (PROSPECT) recommendations.
Eur J Anaesthesiol
October 2023
From the Department of Anaesthesiology, Cliniques Universitaires St Luc, University Catholic of Louvain, Brussels, Belgium (FPM, PML, GP), Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, Texas, USA (GPJ), Department of Anaesthesia and Intensive Care Medicine, Oslo University Hospital, Norway (ARS), Department of Anaesthesiology and Pain Therapy, Bern University Hospital - Inselspital, Bern, Switzerland (ARS), and Department of Cardiovascular Sciences, Section Anaesthesiology, KULeuven and UZLeuven, Leuven, Belgium (VdV).
Background: Pain after craniotomy can be intense and its management is often suboptimal.
Objectives: We aimed to evaluate the available literature and develop recommendations for optimal pain management after craniotomy.
Design: A systematic review using procedure-specific postoperative pain management (PROSPECT) methodology was undertaken.
Pregabalin can interact synergistically with Kv7 channel openers to exert antinociception in mice.
Eur J Pharmacol
September 2023
Jiangsu Key Laboratory of Marine Biological Resources and Environment, Jiangsu Key Laboratory of Marine Pharmaceutical Compound Screening, School of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China; Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Jiangsu Ocean University, Lianyungang, 222005, China. Electronic address:
Chronic pain is a common public health problem and remains an unmet medical need. Currently available analgesics usually have limited efficacy for the treatment of chronic pain, including neuropathic pain and persistent inflammatory pain, or they are accompanied by many adverse side effects. The voltage-gated calcium channel blocker (pregabalin) and potassium channel openers (flupirtine and retigabine) have been widely used for the management of chronic pain, but their effectiveness in combination is unclear.
View Article and Find Full Text PDFThe novel K7 channel activator URO-K10 exerts enhanced pulmonary vascular effects independent of the KCNE4 regulatory subunit.
Biomed Pharmacother
August 2023
Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Institute of Health Research Gregorio Marañón (IiSGM), Madrid, Spain; CIBER Enfermedades Respiratorias (Ciberes), Madrid, Spain.
K7 channels exert a pivotal role regulating vascular tone in several vascular beds. In this context, K7 channel agonists represent an attractive strategy for the treatment of pulmonary arterial hypertension (PAH). Therefore, in this study, we have explored the pulmonary vascular effects of the novel K7 channel agonist URO-K10.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!